
    
      This is an open-label pilot study of omega-3 fatty acids (Lovaza) for hypertriglyceridemia in
      subjects who have been on an atypical (second generation) antipsychotic medication. Eligible
      subjects include men and women, ages 18-75, who have been taking an atypical antipsychotic
      for at least three months prior to enrollment. Atypical antipsychotics include: clozapine
      (Clozaril), olanzapine (Zyprexa), risperidone (Risperdal), aripiprazole (Abilify),
      ziprasidone (Geodon), quetiapine (Seroquel), paliperidone (Invega), asenapine (Saphris),
      iloperidone (Fanapt), and lurasidone (Latuda). Eligible subjects must also have serum
      triglycerides >200 mg/dl or high cholesterol >250 mg/dl at baseline.
    
  